Summary of Key Points
Moderna, in collaboration with Merck Sharp & Dohme, has successfully developed an individualized mRNA tumor vaccine called Intismeran. In a Phase III trial for post-surgery adjuvant therapy of melanoma, it was proven to reduce the risk of recurrence more effectively than using PD-1 drugs alone. This marks the first successful Phase III trial for an mRNA tumor vaccine, which has significantly boosted the global pharmaceutical capital markets (Moderna’s stock price soared by 176%, and related companies in both A-share and Hong Kong stock markets also saw substantial gains). The success validates the potential of mRNA technology in cancer treatment, but there are still two major challenges: first, whether this approach can be extended to more common cancers such as lung and liver cancer; second, the high cost of producing personalized vaccines for each patient makes commercialization difficult. Chinese companies are also making progress and have the potential to gain a competitive advantage by leveraging their large sample pools and skilled engineers.
Why Did the Trial’s Success Drive the Capital Markets Wild?
This trial is equivalent to issuing a “birth certificate” for the mRNA tumor vaccine sector. Although mRNA tumor vaccines have been under research for many years, there had been no successful Phase III trials, leading to doubts about their practicality. Now, Moderna has demonstrated that combining mRNA-based personalized vaccines with PD-1 drugs can significantly reduce the risk of recurrence in melanoma patients (meeting the primary trial objective). This breakthrough has dispelled skepticism and given investors hope for commercialization, considering the massive market potential in cancer treatment. As a result, Moderna’s stock price increased by 176% in one day, triggering a surge of 20% limit-up gains in the A-share biotech sector, while companies like Innovent Biologics and CanSino Biologics in Hong Kong also saw increases of over 30%. The market sees this as a highly valuable opportunity.
How Are Personalized mRNA Tumor Vaccines “Customized”?
In simple terms, these vaccines are tailored for each patient:
1. Sample Collection and Identification: Tissue samples are taken from the patient, and genetic sequencing is used to identify unique mutations in the tumor (similar to a person’s fingerprint, which is distinct from other tumors).
2. Target Selection and mRNA Synthesis: From these mutations, 34 most recognizable “bad molecule markers” (called neoantigens) are selected to synthesize an mRNA strand.
3. Immune Response Activation: The synthesized mRNA is then administered as a vaccine to stimulate the body to produce T cells that specifically target these mutations and eliminate any remaining cancer cells.
Unlike traditional vaccines (such as the COVID-19 vaccine, which provide a one-size-fits-all defense against the virus), personalized mRNA vaccines are designed for each individual patient’s specific tumor.
Did the COVID-19 Pandemic Help Advance mRNA Tumor Vaccines?
Yes! The pandemic has accelerated the development of mRNA technology:
- Improved AI Prediction: The diversity of tumor mutations has led to more accurate predictions by AI, which can quickly identify effective neoantigens from patient tumors (a process that was previously time-consuming).
- Enhanced Delivery Technologies: The LNP (lipid nanoparticle) delivery system used in COVID-19 vaccines has also been adapted for mRNA vaccines, allowing for more efficient cell penetration.
These advancements, driven by the need to develop effective COVID-19 vaccines, have lowered the technical barriers for mRNA tumor vaccines, making this trial a success.
What Are the Remaining Challenges?
The success of the trial is just the first step; commercialization requires solving two key issues:
1. Broaden Application to Other Cancers: This trial focused on melanoma, which has high immunogenicity and was used in post-surgery adjuvant therapy (with fewer residual tumors). The effectiveness of the vaccine in less immunogenic cancers like lung and liver cancer remains to be determined and will require further testing.
2. Cost Reduction: Personalized vaccines are expensive due to the complex production process (sequencing and synthesis for each patient). The industry is working on optimizing production methods or developing “universal” vaccines that can be used by multiple patients. For example, Innovent Biologics’ EVM14 is a universal vaccine currently in clinical trials.
Do Chinese Companies Have a Chance to Overtake?
Yes! China has two significant advantages:
- Large Sample Pool: With a large number of cancer patients, China can provide more tumor samples, which helps improve the accuracy of AI models for vaccine development.
- Engineering Advantages: R&D costs are lower compared to Europe and the United States, and Chinese companies have made technological breakthroughs. For instance, Shagri Biotech’s GT601 has entered clinical trials, while HengnuoKang has solved patent issues related to mRNA capping and lipid formulation, potentially reducing production costs.
In summary, the success of mRNA tumor vaccines is a milestone, but there is still a long way to go before they become widely available in hospitals. However, this breakthrough opens up new possibilities for cancer treatment and holds great promise for the future.